ethyl 4-benzoyl-1H-pyrrole-2-carboxylate | 119647-84-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 4-benzoyl-1H-pyrrole-2-carboxylate
• CAS: 119647-84-6
• 化学式: C₁₄H₁₃NO₃
• 分子量: 243.262
• InChiKey: AKGPFUFYYZPTQT-UHFFFAOYSA-N

物化性质

• 沸点：
  434.8±30.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-benzoyl-1H-pyrrole-2-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 12.0h， 以100%的产率得到4-苯甲酰基-1H-吡咯-2-羧酸
  参考文献：
  名称：

  2-Aminobenzimidazoles as potent ITK antagonists: de novo design of a pyrrole system targeting additional hydrogen bonding interaction

  摘要：

  Based on information from molecular modeling, a series of 2-aminobenzimidazoles with pyrrole moieties were designed and synthesized as ITK antagonists. Results showed that a significant improvement of intrinsic and cell-based potency was achieved. X-ray crystallographic analysis of an inhibitor complex with ITK confirmed the prediction from the de novo design that the pyrrole moiety of the inhibitor would form an additional hydrogen bonding interaction with Glu436 in the catalytic domain, and hence improve overall binding affinity of the inhibitor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.10.057
• 作为产物：
  描述：

  苯乙酮 在 manganese(II) acetate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 ethyl 4-benzoyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  Mn(OAc)2-促进烯胺酮与异氰乙酸酯的[3+2]环化：快速获得具有有效抗癌活性的吡咯-2-羧酸酯衍生物

  摘要：

  开发了实用且简便的Mn(OAc) 2促进的烯胺酮与异氰乙酸酯的[3+2]环加成反应，产生了多种具有广泛底物范围的3-芳酰基吡咯-2-羧酸酯。大多数新合成的化合物对四种癌细胞表现出中等的抗增殖活性。值得注意的是，化合物2n对四种不同的癌细胞系表现出最有效的活性，平均 IC 50值为 5.61 μM。此外，2n表现出良好的抗迁移活性和药物样特性。进一步的研究表明，化合物2n具有抑制ERK5活性的能力，并表现出与ERK5蛋白的有效结合，使其成为一类新型ERK5抑制剂发现的先导化合物的有希望的候选者。

  DOI：

  10.1016/j.bioorg.2023.106748

文献信息

• Pyrrole and pyrazole DAAO inhibitors
  申请人：Fang Kevin Q.

  公开号：US20050143443A1

  公开（公告）日：2005-06-30

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.

  增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法，用于增强学习、记忆和/或认知能力，或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病性疼痛，或预防神经元功能丧失，这涉及向需要治疗的受试者施用化合物I的治疗有效量，或其药学上可接受的盐或溶剂：其中R1和R2独立地选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5；或R1和R2共同形成一个5、6、7或8-成员的取代或未取代的碳环或杂环基团；X和Y独立地选自O、S、NH和(CR6R7)n；R3为氢、烷基或M+；M为铝、钙、锂、镁、钾、钠、锌离子或其混合物；Z为N或CR4；R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5；R5选自芳基、取代芳基、杂环芳基和取代杂环芳基；R6和R7独立地选自氢和烷基；n为1到6的整数；R1、R2和R4中至少有一个不是氢；X和Y中至少有一个是(CR6R7)n。 D-丝氨酸或环丝氨酸可以与化合物I的共同给药。
• Nano-copper catalysed highly regioselective synthesis of 2,4-disubstituted pyrroles from terminal alkynes and isocyanides
  作者：Dipak Kumar Tiwari、Jaya Pogula、B. Sridhar、Dharmendra Kumar Tiwari、Pravin R. Likhar

  DOI：10.1039/c5cc04166j

  日期：——

  Nano-copper(0) stabilized on alumina prepared from Cu–Al hydrotalcite has been reported for completely regioselective synthesis of 2,4-disubstituted pyrroles from unactivated terminal aromatic/aliphatic alkynes and isocyanides.

  从Cu-Al水滑石制备的氧化铝上稳定的纳米铜(0)已被报道用于从未活化的末端芳香/脂肪炔烃和异氰酸酯完全区域选择性合成2,4-二取代吡咯。
• Synthetic Studies on Indoles and Related Compounds. XXXVIII. .BETA.-Acylation of Ethyl Pyrrole-2-carboxylate by Friedel-Crafts Acylation: Scope and Limitations.
  作者：Masanobu TANI、Takahiro ARIYASU、Chika NISHIYAMA、Hiroko HAGIWARA、Toshiko WATANABE、Yuusaku YOKOYAMA、Yasuoki MURAKAMI

  DOI：10.1248/cpb.44.48

  日期：——

  The Friedel-Crafts acylation of ethyl pyrrole-2-carboxylate (3) was studied under several conditions using various Lewis acids and acyl chlorides. The acylation with various acyl chlorides in the presence of aluminum chloride gave exclusively ethyl 4-acylpyrrole-2-carboxylate (5), whereas weaker Lewis acids such as zinc chloride and boron trifluoride etherate gave a mixture of ethyl 4- and 5-acylpyrrole-2-carboxylates.

  在多种条件下，使用各种路易斯酸和酰基氯对吡咯-2-羧酸乙酯（3）的弗里德尔-卡夫酰化进行了研究。在有氯化铝存在的情况下，用各种酰基氯进行酰化反应，只得到 4-酰基吡咯-2-羧酸乙酯（5），而用氯化锌和三氟化硼醚酸等较弱的路易斯酸进行酰化反应，则得到 4-酰基吡咯-2-羧酸乙酯和 5-酰基吡咯-2-羧酸乙酯的混合物。
• Pyrrole and Pyrazole DAAO Inhibitors
  申请人：Fang Q. Kevin

  公开号：US20100016397A1

  公开（公告）日：2010-01-21

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.

  增加D-丝氨酸浓度并减少D-丝氨酸氧化产物浓度的方法，以增强学习、记忆和/或认知能力，或治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛，或预防神经退行性疾病特征性神经元功能损失，包括向需要治疗的受试者施用公式I的化合物或其药学上可接受的盐或溶剂的治疗有效量：其中，R1和R2分别选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5；或R1和R2共同形成5、6、7或8成员取代或未取代的碳环或杂环基；X和Y分别选自O、S、NH和（CR6R7）n；R3为氢、烷基或M+；M为铝离子、钙离子、锂离子、镁离子、钾离子、钠离子、锌离子或其混合物；Z为N或CR4；R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5；R5选自芳基、取代芳基、杂芳基和取代杂芳基；R6和R7分别选自氢和烷基；n为1到6的整数；R1、R2和R4中至少有一个不是氢；X和Y中至少有一个是（CR6R7）n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
• PYRROLE AND PYRAZOLE DAAO INHIBITORS
  申请人：FANG Q. Kevin

  公开号：US20110092559A1

  公开（公告）日：2011-04-21

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.

  增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法，以增强学习、记忆和/或认知能力，或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛，或预防神经退行性疾病特征性神经元功能丧失，包括向需要治疗的受试者施用公式I的化合物的治疗有效量，或其药学上可接受的盐或溶剂：其中，R1和R2分别选自氢、卤、硝基、烷基、酰基、烷基芳基和XYR5；或R1和R2一起形成一个5、6、7或8成员的取代或未取代的碳环或杂环基；X和Y分别选自O、S、NH和（CR6R7）n；R3是氢、烷基或M+；M是铝、钙、锂、镁、钾、钠、锌离子或其混合物；Z是N或CR4；R4选自氢、卤、硝基、烷基、烷基芳基和XYR5；R5选自芳基、取代芳基、杂芳基和取代杂芳基；R6和R7分别选自氢和烷基；n是1到6的整数；R1、R2和R4中至少有一个不是氢；X和Y中至少有一个是（CR6R7）n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。